Physician profile
Amy C Schefler
NPI 1609079367
$17,349.86
in general payments reported to CMS, 2019-2025
14 companies · $4,503 in 2025
The $4,503 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,075 · 2020: $4,341 · 2021: $84.29 · 2022: $3,326 · 2023: $265 · 2024: $1,757 · 2025: $4,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,820 · Consulting Fee: $1,650 · Food and Beverage: $843 · Travel and Lodging: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,820.00 |
| Consulting Fee | $1,650.00 |
| Food and Beverage | $843.47 |
| Travel and Lodging | $211.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $4,476.14 | 2019-2024 | Eylea |
| Immunocore Limited | $4,319.54 | 2025 | Kimmtrak |
| Bausch & Lomb Americas INC. | $3,044.40 | 2022-2024 | Miebo, Xiidra |
| Allergan, INC. | $1,764.13 | 2019-2022 | |
| Abbvie INC. | $1,738.39 | 2023-2025 | Ozurdex |
| Optos, INC. | $1,000.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $307.25 | 2020-2025 | Eylea Hd, Eylea, Dupixent |
| Genentech USA, INC. | $236.36 | 2019-2025 | Vabysmo |
| Iridex Corporation | $155.85 | 2022-2023 | |
| Eyepoint US, INC. | $135.00 | 2022 | |
| Spark Therapeutics, INC. | $81.82 | 2019 | |
| Apellis Pharmaceuticals, INC. | $42.12 | 2022-2023 | |
| Genentech, INC. | $30.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Schefler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.